Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098521 | 0.96 | NPC1 (0.33) | NPC1MAPTDGAT1AKR1B10KDM4E | |
| SCHEMBL4092544 | 0.92 | ALDH1A1 (0.35) | NPC1MAPTKDM4EALDH1A1 | |
| SCHEMBL5760757 | 0.82 | KDM4E (0.33) | DGAT1KDM4EALDH1A1 | |
| SCHEMBL13740523 | 0.81 | EGLN1 (0.35) | NPC1KDM4EALDH1A1 | |
| SCHEMBL4101690 | 0.81 | DPP4 (0.35) | MAPTKDM4EALDH1A1 | |
| SCHEMBL4101641 | 0.79 | DPP4 (0.34) | KDM4EALDH1A1 | |
| SCHEMBL5761967 | 0.79 | KDM4E (0.33) | DGAT1KDM4EALDH1A1 | |
| SCHEMBL4103659 | 0.78 | DPP4 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL4096907 | 0.78 | KDM4E (0.35) | MAPTKDM4EALDH1A1 | |
| SCHEMBL4097775 | 0.77 | HRH3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | NPC1 4245/4885MAPT 2554/4885DGAT1 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.